Category: TCTMD Articles

RE-DUAL PCI Findings Consistent Across Key Subgroups

November 16, 2017

“Dabigatran-based dual antithrombotic therapy maintains its advantage over warfarin-based triple therapy in terms of reducing bleeding in patients with A-fib undergoing PCI, a new analysis of RE-DUAL PCI shows. That advantage is held across patient subsets.”

Visit Website